HDAC inhibitors that enhance acetylation and gene transcription are currently being evaluated in various stages of clinical trials for TNBC/metastatic cancers (NCT02890069, NCT02708680, NCT04315233, and NCT04296942) (https://clinicaltrials.gov). This evidence concerns the gene HDAC9 and metastatic malignant neoplasm.